A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
Status:
Completed
Trial end date:
2018-10-29
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with
local advanced or metastatic HER2 positive endothelial cancer.